Repare Therapeutics shares rise by 25% after it announced its collaboration deal with Roche

0

Repare Therapeutics shares rise by 25% after it announced its collaboration deal with Roche | Invezz

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >

By:

Ruchi Gupta

on
Jun 4, 2022

It executed a collaboration and worldwide license deal with Roche

Roche will be responsible for the development of RP-3500 with the opportunity to expand development efforts.

Repare Therapeutics will get an upfront payment of about $125 million.

Repare Therapeutics Inc (NASDAQ: RPTX), a top clinical-stage precision oncology corporation, announced that it’s executed a collaboration and worldwide license deal with Roche for both the commercialization and development of RP-3500 (also known as camonsertib). This new shot up the company’s stock price by 25%.

Camonsertib is a selective and potent oral tiny molecule inhibitor of Rad3 and Ataxia-Telangiectasia based protein kinase which is designed to treat tumors using synthetic-lethal genomic alterations. Under the collaboration agreement, Roche will be responsible for the development of RP-3500 with the opportunity to expand development efforts into additional tumors.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

How does top management feel?

Repare Therapeutics’ Head of Business & Corporate Development and Executive Vice President, Kim Seth, said:

Given the encouraging data Repare has generated for camonsertib as a potentially best-in-class ATR inhibitor with a promising tolerability profile and patient selection insights in areas of high unmet medical need… we are confident that Roche is the ideal partner for us to drive the broad global development and commercialization of camonsertib.

The EVP claims that RP-3500 has the potential to treat people with cancer across several solid tumor issues as a monotherapy. James Sabry, Roche’s Global Head of Pharma Partnering, said:

We are looking forward to partnering with Repare Therapeutics to further develop camonsertib as a new potential treatment option for patients with significant unmet medical needs across a range of tumor types. The collaboration with Repare builds on Roche’s strategy of personalized healthcare and further strengthens our leadership in oncology.

Details of the agreement

According to the collaboration deal, Repare Therapeutics will get an upfront payment of about $125 million, and the company is eligible to get as much as $1.2 billion in sales, commercial, regulatory and clinical milestones, including up to around $55 million in near-term payments, as well as any royalties from worldwide net sales that range from high teens to high-single-digits.

The collaboration deal also offers Repare Therapeutics with the chance to access a 50-50 United States profit share and co-development arrangement. If the company opts to exercise this option, it will be eligible to receive certain milestone payments.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,
Capital.com

9.3/10

75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Visit site

Health & pharmaceuticals


Stocks & Shares

Generated by Feedzy